Covington and Amarin management also had years leading up to the trial to do an analysis like the one Dr. Bhatt produced post trial. That would have evidenced Mori and Kura (according to HK) were both statistically irrelevant and without value. It sure would have weakened the generics case. It also would have meant the cropped table and Dr. Heinecke’s false testimony would have been nipped in the bud. I like this approach better. The patient population being different doesn’t impress me. I should have listened to JL and bailed out at 18. I see our buyout value at $10 per share. I'd take that to end this misery.
Market Data 
Markets 
AI
